FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
FDA General

FDA Should Consider Free Speech Decisions: MIWG

The Medical Information Working Group says FDA should incorporate principles from five recent Supreme Court free speech decisions into its considerati...

Federal Register

Oncology Panel Review AstraZeneca, Merck

Federal Register notice: FDA announces a 12/17 Oncologic Drugs Advisory Committee meeting that with discuss an AstraZeneca supplemental NDA for Lynpar...

Human Drugs

Rising Pharma Paying Over $3 Million in Price Fixing Charge

The Justice Department says Rising Pharmaceuticals will pay over $3 million to resolve price fixing charges and will cooperate with an ongoing investi...

Human Drugs

Tecentriq/Chemo Combo OKd for Lung Cancer

FDA approves a Genentech supplemental BLA for Tecentriq (atezolizumab) in combination with chemotherapy for the initial treatment of certain adults wi...

Human Drugs

House Drug Price Bill Keeps New Drugs Away: White House

The White House Council of Economic Advisors cautions that House Democrats drug price bill will keep innovative new drugs off the market.

Medical Devices

Breakthrough for RightEye Parkinsons Test

FDA grants RightEye a breakthrough device designation for the RightEye Vision System and its use in diagnosing Parkinsons Disease.

Human Drugs

Aquestive Therapeutics Rolling NDA for Libervant

Aquestive Therapeutics completes a rolling NDA submission for Libervant (diazepam) Buccal Film for managing seizure clusters.

Medical Devices

Electronic Format Transparency Needed: Comment

AdvaMed urges FDA to be transparent and flexible in developing plans for regulatory submissions in electronic format.

FDA General

Latest FDA Warning Letter

FDA releases its latest batch of Warning Letters that includes one medical product company American Contract Systems.

Human Drugs

House Hearing to Grill FDA on Foreign Inspections

The House Energy and Commerce Oversight and Investigations Subcommittee plans a 12/10 hearing to question FDA on its foreign drug inspection program a...